The safety profile of the combination of AZD8186 with paclitaxel indicated that the treatment was well tolerated; however, the trial ended at phase II due to poor clinical efficacy in advanced gastric cancer patients with mutated PTEN. However, the patients with PIK3CB mutations had greater long-term clinical benefits than their counterparts, indicating that AZD8186-based therapy may have greater clinical efficacy in a small subset of the patient population (i.e., patients overexpressing PIK3CB), but not in all cases of PCa [89]. This evidence concerns the gene PIK3CB and gastric cancer.